Deuterated HER2 Antibody-Drug Conjugates for Soluble Topoisomerase I Payloads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in developing highly potent and low-toxic ADC drugs that can target a wide range of tumor types, particularly due to the inefficiency of enzyme-activated cytotoxic drugs like irinotecan and the poor solubility of SN-38, which limits their effectiveness.
Innovation Solution
The development of an antibody-drug conjugate with a deuterated modification of the linker or cytotoxic drug moiety, specifically targeting HER2-expressing cells using modified antibodies and cytotoxic agents such as camptothecin analogs, which are linked via various cleavable and non-cleavable linkers, enhancing potency and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin derivatives like SN-38 are used as cytotoxic drug moieties, then high anti-tumor activity against topoisomerase I is achieved, but poor water solubility and inefficient activation limit therapeutic efficacy
Solution Approach 1:
The patent introduces deuterium atoms at specific positions in the camptothecin derivative structure (such as at the C-10 position or in the side chain), changing the isotopic composition parameter. This deuterium substitution improves water solubility while maintaining the drug's ability to inhibit topoisomerase I and form DNA cleavage complexes, thereby resolving the contradiction between solubility and therapeutic efficacy
2Reliability
If deuterated modification is introduced in the linker or cytotoxic drug moiety, then pharmacokinetic properties and safety are improved, but structural complexity increases
Solution Approach 1:
The patent applies deuterium substitution at specific local positions rather than throughout the entire molecule. Deuterium is introduced at key positions such as the C-10 position of camptothecin or specific positions in the linker moiety (such as positions adjacent to carbonyl groups or aromatic rings). This localized deuteriation improves pharmacokinetic properties and reduces toxicity while minimizing the increase in structural complexity, as only critical positions are modified rather than the entire molecular structure
Data Source
AI summary
Provided is an antibody drug conjugate, specifically comprising a therapeutic antibody moiety, an intermediate linker moiety and a cytotoxic drug moiety which are linked. The therapeutic antibody moiety is an antibody against an HER2 target. The cytotoxic drug moiety is a camptothecin topoisomerase I inhibitor. The cytotoxic drug moiety or the linker-cytotoxic drug moiety is modified by means of deuterium substitution. The antibody drug conjugate can be used for the prevention or treatment of cancers.